{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:15Z","timestamp":1760145675501,"version":"build-2065373602"},"reference-count":68,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The health burden of metabolic dysfunction-associated fatty liver disease (MASLD) has been increasing lately. Cardiovascular disease (CVD) is the main cause of death in MASLD patients; therefore, the treatments for MASLD should improve both CV risk factors such as obesity, diabetes, and dyslipidemia, in addition to an improvement in liver function. The evidence on the long-term effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) on the progression of MASLD in Asian populations is very limited. Methods: The retrospective longitudinal study was performed by using the medical records at our institute. We picked up patients with type 2 diabetes who had taken SGLT2is for at least 3 years or longer between 1 April 2014 and 31 March 2018. We collected the data on metabolic parameters, including laboratory data and anthropometric parameters, and compared the data before and after the initiation of SGLT2is treatment. Results: During the observation period, 324 patients had taken SGLT2is for 3 years. Three-year SGLT2is treatment significantly reduced body weight, hemoglobin A1c, low-density lipoprotein cholesterol, triglyceride, and non-high-density lipoprotein cholesterol (non-HDL-C). Such favorable changes in serum lipids were remarkable in patients with statins. Furthermore, this treatment significantly improved liver function and the markers for hepatic steatosis and hepatic fibrosis. Conclusions: Considering that the development of CVD determines the prognosis of MASLD patients, long-term SGLT2is treatment may be an ideal therapy for MASLD patients.<\/jats:p>","DOI":"10.3390\/jcm13164929","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T11:14:41Z","timestamp":1724325281000},"page":"4929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-8340","authenticated-orcid":false,"given":"Hisayuki","family":"Katsuyama","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Horinaka","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Hakoshima","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-3665","authenticated-orcid":false,"given":"Hidekatsu","family":"Yanai","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa 272-8516, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: A consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., Iida, S., and Katsuyama, H. (2023). Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202309.1062.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3748\/wjg.v21.i5.1650","article-title":"Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index","volume":"21","author":"Pang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","article-title":"Sodium glucose co-transporter 2 inhibitors: Blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes","volume":"62","author":"Jabbour","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/jocmr2385w","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering","volume":"8","author":"Yanai","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13098-023-01085-y","article-title":"Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Wang","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature05449","article-title":"The nuclear receptor LXR is a glucose sensor","volume":"445","author":"Mitro","year":"2007","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., and Peiseler, M. (2022). Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052668"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1101\/gad.850400","article-title":"Role of LXRs in control of lipogenesis","volume":"14","author":"Schultz","year":"2000","journal-title":"Genes Dev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/383728a0","article-title":"An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha","volume":"383","author":"Janowski","year":"1996","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1101\/gad.844900","article-title":"Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta","volume":"14","author":"Repa","year":"2000","journal-title":"Genes Dev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ni, M., Zhang, B., Zhao, J., Feng, Q., Peng, J., Hu, Y., and Zhao, Y. (2019). Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease. Biomed. Pharmacother., 113.","DOI":"10.1016\/j.biopha.2019.108778"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s10620-014-3289-x","article-title":"Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease","volume":"59","author":"Ahn","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yin, C., Zhong, R., Zhang, W., Liu, L., Chen, L., and Zhang, H. (2023). The Potential of Bile Acids as Biomarkers for Metabolic Disorders. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512123"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jin, Z., Yin, R., Yuan, Y., Zheng, C., Zhang, P., Wang, Y., and Weng, H. (2024). Dapagliflozin ameliorates hepatic steatosis via suppressing LXR\u03b1-mediated synthesis of lipids and bile acids. Biochem. Pharmacol., 223.","DOI":"10.1016\/j.bcp.2024.116167"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: Functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg2843","article-title":"The widespread regulation of microRNA biogenesis, function and decay","volume":"11","author":"Krol","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: Target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ddr.22020","article-title":"Therapeutic role of Artemether in the prevention of hepatic steatosis through miR-34a-5p\/PPARalpha pathway","volume":"84","author":"Chen","year":"2023","journal-title":"Drug Dev. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"155657","DOI":"10.1016\/j.metabol.2023.155657","article-title":"SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis","volume":"146","author":"Shen","year":"2023","journal-title":"Metabolism"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Androutsakos, T., Nasiri-Ansari, N., Bakasis, A.D., Kyrou, I., Efstathopoulos, E., Randeva, H.S., and Kassi, E. (2022). SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063107"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Use of the Fib4 index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Aoki, N., and Kanemasa, K. (2012). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol., 12.","DOI":"10.1186\/1471-230X-12-2"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"176087","DOI":"10.1016\/j.ejphar.2023.176087","article-title":"The impact of sodium-glucose Cotransporter-2 inhibitors on lipid profile: A meta-analysis of 28 randomized controlled trials","volume":"959","author":"Fan","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"117236","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103633","DOI":"10.1016\/j.amsu.2022.103633","article-title":"Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis","volume":"77","author":"Dar","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105068","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.14740\/jocmr2467w","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis","volume":"8","author":"Katsuyama","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.14740\/jocmr3046w","article-title":"Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data","volume":"9","author":"Yanai","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1067\/mhj.2002.130301","article-title":"High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease","volume":"144","author":"Gotto","year":"2002","journal-title":"Am. Heart. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/jdi.14179","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on serum low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus","volume":"15","author":"Imada","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wang, D., Liu, J., Zhong, L., Li, S., Zhou, L., Zhang, Q., Li, M., and Xiao, X. (2022). The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1045235"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","article-title":"The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus","volume":"1","author":"Randle","year":"1963","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Yanai, H., and Yoshida, H. (2019). Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051190"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"eBioMedicine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., and Katsuyama, H. (2022). Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113499"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/jem632","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients with Type 2 Diabetes: A Chart-Based Analysis","volume":"10","author":"Katsuyama","year":"2020","journal-title":"J. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/hepr.13898","article-title":"Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB-4 index in metabolic-associated fatty liver disease","volume":"53","author":"Mino","year":"2023","journal-title":"Hepatol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ito, D., Shimizu, S., Haisa, A., Yanagisawa, S., Inoue, K., Saito, D., Sumita, T., Yanagisawa, M., Uchida, Y., and Inukai, K. (J. Diabetes Investig., 2024). Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD, J. Diabetes Investig., online ahead of print.","DOI":"10.1111\/jdi.14246"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep4.2005","article-title":"Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study","volume":"9","author":"Akuta","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"11","author":"Arai","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","article-title":"Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"JAAPA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Knudsen, L.B., and Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00155"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"108743","DOI":"10.1016\/j.jdiacomp.2024.108743","article-title":"Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials","volume":"38","author":"Xie","year":"2024","journal-title":"J. Diabetes Complicat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pcd.2024.03.005","article-title":"Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"18","author":"Fang","year":"2024","journal-title":"Prim. Care Diabetes"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"91319","DOI":"10.5662\/wjm.v14.i2.91319","article-title":"Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies","volume":"14","author":"Pramanik","year":"2024","journal-title":"World J. Methodol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bao, J., Zhao, Y., Xu, X., and Ling, S. (Curr. Med. Chem., 2024). Advance of Metformin in Liver Disease, Curr. Med. Chem., online ahead of print.","DOI":"10.2174\/0109298673274268231215110330"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2174\/1381612827666210315144821","article-title":"The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis","volume":"27","author":"Hu","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e31437","DOI":"10.1097\/MD.0000000000031437","article-title":"Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology","volume":"101","author":"Huang","year":"2022","journal-title":"Medicine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/07435800.2020.1713802","article-title":"Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice","volume":"45","author":"Tahara","year":"2020","journal-title":"Endocr. Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Caturano, A., Galiero, R., Loffredo, G., Vetrano, E., Medicamento, G., Acierno, C., Rinaldi, L., Marrone, A., Salvatore, T., and Monda, M. (2023). Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020322"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:40:16Z","timestamp":1760110816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":68,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13164929"],"URL":"https:\/\/doi.org\/10.3390\/jcm13164929","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,8,21]]}}}